Keywords
How to Cite
Abstract
Introduction: Lecanemab is a monoclonal antibody used in the treatment of Alzheimer's disease, specifically on soluble beta-amyloid oligomers, with the aim of facilitating removal from the immune system, reducing the load of beta-amyloid in the brain. Objective: to evaluate the impacts of lecanemab in the treatment of Alzheimer's Disease. Methods: It consists of an integrative review carried out through the Scopus, PubMed® and SciELO databases, using the descriptors Lecanemab, Alzheimer's disease and anti-beta-amyloid. Studies published in the last 9 years, in English, Spanish or Portuguese, that addressed the topic were included. Results: Lecanemab showed consistent efficacy in reducing cerebral amyloid plaques, associated with Alzheimer's disease, in addition to cognitive and functional benefits. However, there were some adverse effects such as infusion-related and occurrence of amyloid imaging-related abnormalities. Considerations: Lecanemab demonstrates greater efficacy than placebo in reducing Aβ burden in early stages of AD, with a significant impact on reducing amyloid plaques and delaying cognitive decline. The drug was well tolerated, resulting in an acceptable safety profile. However, despite promising results, long-term studies are needed to fully evaluate its safety and efficacy profile.
References
ABUSHOUK, A. I. et al. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. BMC Neurology, v. 17, p. 66, 2017.
ALEXIOU, A.; CHATZICHRONIS, S.; ASHRAF, G. M. Prediction of Alzheimer's disease. In: MARTIN, C. R.; PREEDY, V. R. (Ed.). Diagnosis and Management in Dementia. Boston: Academic Press, 2020. p. 365–378.
ANGELUCCI, F. et al. Antibiotics, gut microbiota, and Alzheimer's disease. Journal of Neuroinflammation, v. 16, p. 108, 2019.
ATWOOD, C. S.; PERRY, G. Russian roulette with Alzheimer's disease patients: do the cognitive benefits of lecanemab outweigh the risk of edema and stroke? Journal of Alzheimer's Disease, v. 92, p. 799–801, 2023.
CUMMINGS, J. L. et al. The costs of developing treatments for Alzheimer's disease: a retrospective exploration. Alzheimer's & Dementia, v. 18, n. 3, p. 469–477, 2022.
FULOP, T. et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease? Frontiers in Aging Neuroscience, v. 10, p. 224, 2018.
KHAN, U. A. et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nature Neuroscience, v. 17, p. 304–311, 2014.
LOGOVINSKY, V. et al. Safety and tolerability of BAN2401 - A clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimer's Research & Therapy, v. 8, 2016.
LU, J. X. et al. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell, v. 154, p. 1257–1268, 2013.
LU, L. et al. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, v. 91, p. 1316–1324, 2020.
MCDADE, E. et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's Research & Therapy, v. 14, p. 191, 2022.
MULTHAUP, G.; HUBER, O.; BUÉE, L.; GALAS, M. C. Amyloid precursor protein (APP) metabolites APP intracellular fragment (AICD), Aβ42, and tau in nuclear roles. Journal of Biological Chemistry, v. 290, p. 23515–23522, 2015.
OLIVARES, D. et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Current Alzheimer Research, v. 9, p. 746–758, 2012.
PEREIRA, J. B. et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, v. 144, p. 2826–2836, 2021.
SERRANO-POZO, A. et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, v. 1, p. a006189, 2011.
ZHU, F. et al. Target dysbiosis of gut microbes as a future therapeutic manipulation in Alzheimer's disease. Frontiers in Aging Neuroscience, v. 12, p. 544235, 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Victória Souza Marques , Ricardo Vieira Bittencourt, Cecília Soares de Oliveira, Julyana Eulália Pereira Pessoa, Maria Ester Gonçalves Ferreira Cavalcanti Manso, Bruno Oliveira Góes, Camilla Catarina Braz de Albuquerque pontes Lopes, Leticia Melo Guimarães Pinto, Wilson Moraes Amaral Júnior, Rostand Ramos de Lima Cavalcanti Filho, Hulfshoff Damasceno Gama, Paulo Brian Fagundes, João Vítor Tomaz Ribeiro, Franciele Rabelo Braga, Maria Eduarda Lapa Nogueira Lima, Walter Borges de Almeida, Natália Caminha Freire de Albuquerque, Bruna Lima Farias Batista